Cardiovascular disease (CVD) after transplantation remains a major concern. Little is known about what drives the increased cardiovascular risk in transplant recipients apart from traditional risk factors. The immune system is involved in the pathogenesis of hypertension, atherosclerosis, and coronary artery disease in the general population. Recently, inhibition of interleukin 1 À b by canakinumab versus placebo decreased the incidence of cardiovascular events. Emerging evidence points to a role of adaptive cellular immunity in the development of CVD. Especially, expansion of pro-inflammatory and antiapoptotic cytotoxic CD4
Introduction
Both innate and adaptive immunity are important in the pathophysiology of cardiovascular disease (CVD) [1] . Compelling evidence, mainly derived from animal models or autoimmune diseases, supports the notion that immunological alterations directly promote atherosclerosis [1] . Immunological disturbances may also indirectly contribute to CVD by causing or amplifying traditional risk factors such as hypertension and diabetes [2] . Considering the high cardiovascular burden after transplantation, the role of immunodeficiency and the variable effects of immunosuppressive drugs on particularly the T-cell repertoire deserve further attention [3] .
The simplified concept of atherosclerosis as a process of lipid deposition with macrophage infiltration and formation of foam cells has been reformulated. We should acknowledge that these models most likely but not certainly are valid for transplant recipients. Briefly, dyslipidemia still plays a central role as trapped oxidized low-density lipoprotein (ox-LDL) cholesterol particles in the subendothelium trigger an immune response by recruiting monocyte-derived macrophages and lymphocytes ( Fig. 1 ) [1] . Macrophages in the plaque fuel the production of pro-inflammatory cytokines such as interleukin (IL)-6 via the formation of foam cells and the activation of vascular smooth muscle cells (VSMC) [1] . Dendritic cells (DC) guide the differentiation of T cells toward maturation, anergy, death, or a regulatory (Treg) phenotype [4] . The response and distribution of T cells are not only anchored to the innate immune response but also to the local cytokine environment [1] . Inflammation will favor differentiation of T cells into pro-inflammatory TH1 cells with increased expression of tumor necrosis factor (TNF)-a and interferon (IFN)-ɣ rather than into antiatherogenic TH2 or Tregs [1] . In the peripheral blood of patients with CVD, the proportion of reactive effector memory T cells is consistently increased [4] . T cells in atherosclerotic lesions of patients with coronary artery disease (CAD) are characterized by ongoing antigen-driven immune response with ox-LDL, apolipoprotein B100-derived, and other unraveled antigens acting as neoepitopes promoting the development of high-affinity antibodies, resulting in local inflammation [1, 4] . Adaptive immunity is pivotal not only in plaque formation, with a role of especially CD4 + rather than less abundant activated CD8 + T cells but also in plaque instability and rupture [5] . CD4 + T lymphocytes, especially CD4 + CD28 null T cells, accumulate in unstable plaque and endothelial erosions, potentially triggering coronary events [1, 4] . In patients with acute coronary syndrome (ACS), effector T cells have molecular fingerprinting of recent IFN-ɣ signaling [6] . Atherosclerosis shares features with inflammatory and autoimmune diseases, while both infection and autoimmunity promote vascular inflammation and endothelial dysfunction [4] .
It seems likely that the same mechanisms are at play in solid organ transplant (SOT) recipients. Genotypes associated with increased or decreased local or systemic production of, respectively, TNF-a and IL-10, the most potent downregulator of pro-inflammatory cytokines, were associated with more CVD in kidney transplant recipients (KTR) after adjustment for confounders including C-reactive protein (CRP) [3] . Genetic susceptibility to CAD has been associated with variable immunological responses of vascular cells to cytokines such as IFN-ɣ [7, 8] . CRP sensitizes endothelial cells to T-cell-mediated cytotoxicity in vitro and pretransplant CRP values are associated with cardiac events in KTR [9] . In this review, we will discuss emerging immunological concepts in the pathophysiology of atherosclerotic disease. We aim at integrating recent clinical findings in SOT into experimental models and will compare studies among various SOT recipients.
The role of the costimulatory pathway in atherosclerosis
Crucial in the immune response is the costimulatory signal by the contact between antigen-presenting cell (APC) CD80/86 ligands with T-cell adhesion molecules (particularly CD28). Of interest here is angiotensin II-mediated overexpression of CD80/CD86 on DC, promoting inflammation and atherosclerosis [2] . Inhibition of these triggered DC decreases the accumulation of macrophages and activated T lymphocytes into the plaques decreasing secretion of IFN-ɣ, an important mediator of plaque destabilization. Cytotoxic lymphocyte antigen-4 (CTLA-4), a CD28 homolog albeit with functional dichotomy, and the CTLA-4/IgG1 fusion protein abatacept both attenuate the inflammatory response and the accelerated formation of atherosclerosis in mice by high-affinity binding to and downregulation of the CD80/86 ligands [10, 11] . This seems relevant for SOT as belatacept blocks the costimulatory pathway due to the interaction between CD28 and CD80/86 ligands. Tregs suppress the immune response partially by CTLA-4-dependent downregulation of these ligands [12] . Apolipoprotein E knockout (ApoE-/) mice typically overexpress CTLA-4 and develop less atherosclerosis than control breeds [13] . Also, infusion of CTLA-4/ IgG improves angiotensin II-induced hypertension in rats [2] . CTLA-4 bears potential as a relevant target in the therapeutic approach of atherosclerosis while CTLA-4 blockade by checkpoint inhibitors such as ipilimumab seem cardiotoxic [14] .
The role of adaptive T-cell immunity
Emerging data point to a causal role of these terminally differentiated effector T cells in the pathophysiology of atherosclerosis and ACS, of which half of the patients have an abnormal T-cell distribution [15] . In healthy humans, the concentration of CD4 + CD28 null cells, a subset of TH1 cells and the main biological indicator of immunological aging, is very low [16] . Permanent loss of CD28 expression on CD4 + cells is antigen-driven or occurs through aging [17] . Inflammatory conditions such as diabetes, rheumatological disorders, and chronic kidney disease (CKD) share, often in conjunction with a lower fraction of Tregs, an expansion of these cardiotoxic cells which are independently associated with all-cause, cardiovascular mortality, and/or cardiovascular events in various populations including patients with heart failure, unstable angina, and recurrent coronary events [18] [19] [20] . These plaque-destabilizing cells which catalyze inflammation are numerous in rupture-prone atherosclerotic plaques [18] . They share cytotoxic characteristics with CD8 + T cells and natural killer (NK) cells as they produce cytolytic enzymes such as perforin and granzyme B and express the activating cytotoxicity receptor NKG2D, enabling them to kill endothelial cells and VSMC [21] . Also contributing to plaque destabilization they, unlike CD4 + CD28 + T helper cells, express markers of endothelial homing such as the fractalkine receptor CX3C chemokine receptor 1 (CX3CR1) [21] . They are less resistant to pro-apoptotic effects of Tregs [15, 16] . TNF-a, whose plasma concentration is associated with mortality in heart failure, downregulates CD28 expression on CD4 + T lymphocytes and expands these cells, perpetuating a positive loop [22] These atheroprotective cells suppress several immune cells involved in atherosclerosis such as B cells, monocytes, and DC [4, 12] . In patients with CAD and especially ACS, they are less common and dysfunctional [12] . Tregs are a major source of the antiatherogenic cytokines IL-10 and TGF-b contributing to powerful suppression of atherosclerosis in murine models [4, 12] . Studies on circulating T-cell subpopulations have methodological caveats, and so variable concentrations should be interpreted cautiously. It is uncertain whether findings in rodents are generalizable to humans [4] . Another limitation particularly in transplant recipients is confounding by kidney dysfunction. In patients with kidney allograft dysfunction, serum concentrations of pro-inflammatory cytokines such as IL-2, IL-17, and IFN-ɣ were higher than in subjects with stable kidney function in whom there was a higher expression of IL-4, IL-10, and Tregs [49] . Therefore, negative outcome in hyperproducers of pro-inflammatory cytokines can be confounded by graft outcome. Instead, chronic inflammation due to rejection can contribute to atherosclerosis.
The role of humoral immunity
B2 cells aggravate atherogenesis through antibodyindependent mechanisms that augment the action of pro-inflammatory cytokines [4] . Emerging data demonstrate that antibodies play an active role. A pathophysiological role for IgE in the development of atherosclerosis was suggested by both clinical and experimental data [50] . Antibodies against oxidized LDL enhance uptake of cholesterol and promote atherosclerosis [1] . Transcripts of endothelial stress disclose the endothelium as target for cellular immunity after transplantation, and non-HLA antibodies also disrupt endothelial homeostasis [51] . The role of humoral auto-and alloimmunity in the pathophysiology of CVD until recently was not well outlined [1] . In epidemiological studies, multiparity, and especially with different fathers, is associated with increased cardiovascular mortality, while blood transfusion from women with a history of pregnancy was associated with an increased mortality in male acceptors, providing indirect evidence for a role of alloimmunity [52, 53] . Allogenic hematopoietic stem cell transplant recipients with versus without pretransplant HLA antibodies had more vascular complications [54] . Following KTR registry data, panel-reactive antibodies (PRA) at the time of transplantation were dose-dependently associated with cardiovascular mortality [55] . The analysis could support the causal paradigm that anti-HLA antibodies induce both a local and general pro-inflammatory state leading to endothelial injury. HLA class II antibodies alter the endothelial expression of the anti-inflammatory and antithrombotic glycoprotein thrombomodulin and lower its serum concentration in KTR [56] . Studies indirectly suggest a pro-atherogenic potential of HLA antibodies. Loupy and coworkers demonstrated that DSA in KTR were dose-dependently associated with increased cardiovascular mortality and cardiac events [57] . Endothelial damage by HLA antibodies or ischemia may lead to a pro-inflammatory phenotype and de novo expression of endothelial neoantigens contributing to immune activation and vascular remodeling [58] . In systemic lupus erythematosus, autoantibodies promote atherosclerosis and cardiac events. However, the presence of HLA and non-HLA antibodies rather than being causative may also reflect activation of adaptive immunity. Pro-atherogenic drug effects possibly are attenuated by beneficial effects on vascular inflammation.
Abatacept and belatacept
In animal models, modulation of costimulatory and coinhibitory signals has beneficial cardiovascular effects. Abatacept decreases CD4 + CD28 null cells in patients with rheumatoid arthritis [32] . In a murine model of heart failure, this beneficial effect on cardiac dysfunction depended upon induction of the anti-inflammatory IL-10 [100]. In humans, it was associated with a decreased risk of myocardial infarction [33] . In KTR, belatacept was associated with a lower incidence of DSA versus cyclosporine, which coincided with a lower incidence of cardiac events and overall mortality [101] .
Rituximab
Adding up to theoretical benefits of corticosteroid avoidance, this drug improved endothelial dysfunction and IMT in patients with rheumatoid arthritis [102] . Paradoxically, it was associated with acute coronary events early after administration attributed to an increase in cytokines including TNF-a in a subset of these patients and increased cardiovascular mortality the first 3 years after kidney transplantation [103, 104] . This could mirror previous findings demonstrating an excessive increase in cellular rejection early after kidney transplantation in accordance with a rise of cytokines [105] . Moreover, rituximab accelerated CAV without a higher incidence of treated rejection in a recent placebo-controlled RCT in unsensitized HTR [106] . Rituximab can possibly increase autoimmunity by decreasing immunoregulatory B cells. Rituximab-specific IgE antibodies and TH2 suggestive of type 1 hypersensitivity have been demonstrated [107] . Other monoclonal antibodies such as bevacizumab and trastuzumab were also associated with cardiac events possibly due to autoimmunity [107] . This conundrum highlights that the role of B cells in allo-and autoimmunity is complex, not always unambiguous and sometimes modified by unrecognized conditions.
Polyclonal induction
B-cell-depleting antibodies and neutralization of B-cellactivating factor (BAFF) were atheroprotective in mice [4, 108] . The situation seems more complex for antithymocyte globulin (ATG), which was associated with proapoptotic effects and a longitudinal decrease in 
Calcineurin inhibitors
Calcineurin inhibitors (CNI) have pro-atherogenic properties primarily because of effects on traditional cardiovascular risk factors [96] . They promote vascular inflammation in murine models by increasing cytokine production through upregulation of TLR4 signaling [114] . CNI impairs Treg proliferation and function after liver and kidney transplantation [43, 44] . Treatment with tacrolimus versus cyclosporine is associated with less DSA formation [112] . In a RCT, withdrawal of CNI in KTR did not improve carotid IMT despite better blood pressure control [115] . CNI withdrawal in KTR was not associated with decreased mortality [116] .
Mycophenolate
In analogy with belatacept, MMF has no effect on traditional cardiovascular risk factors. In a RCT in patients with symptomatic carotid stenosis, a short course of MMF attenuated plaque inflammation, decreased proinflammatory gene expression, and increased circulating Tregs [117] . MMF was associated with lower CRP concentrations in KTR [118] . In liver transplant recipients, use of MMF was associated with a lower cardiovascular mortality [119] . HTR randomized to MMF versus azathioprine has slower 1-year progression of intimal thickening [120] .
mTOR inhibitors
Despite unfavorable metabolic effects, mTOR inhibitors have antiproliferative and cardioprotective properties. HTR allocated to everolimus versus MMF had beneficial effects on intima proliferation at months twelve [121] . CNI avoidance strategies demonstrated beneficial effects on CAV progression, likely due to inhibitory effects on endothelial cells and fibroblasts or by reduction in CMV infection [122] . Also, in parallel with less CAV progression, there was a greater decline of soluble TNFR-1, in HTR allocated to everolimus versus CNI [123] .
In KTR, data are less convincing despite beneficial effects of mTOR inhibitors on cardiac hypertrophy [124] . Cardiovascular outcome or mortality is not lower compared to CNI [116] . Mostly short-term trials focusing on renal endpoints are not powered to detect differences in cardiovascular outcome. Registry data even demonstrated an increased overall mortality in KTR with an mTOR inhibitor-based regimen [125] . In a meta-analysis of individual patient data, KTR on mTOR inhibitors had a higher incidence of CVD although death-censored graft survival was not different [126] . Interestingly, conversion of KTR from tacrolimus to sirolimus not only increased Tregs but also paradoxically increased indirect donor T-cell reactivity activating pro-inflammatory genes, in line with in vivo and in vitro studies in mice [127, 128] . It is unclear to what extent drug-induced hyperlipidemia can counteract cardioprotective properties. Early (<12 months) conversion from CNI to mTOR inhibitors was associated with a higher incidence of DSA [129] .
Conclusion and future prospects
Mounting evidence points to a crucial role of cellular and humoral immunity in the pathogenesis of CVD and mortality in the general population. This is supported by interventional studies demonstrating beneficial effects of anti-inflammatory drugs on both surrogate outcomes and cardiovascular events. In SOT, the situation is more complex as potentially protective effects of immunosuppressive drugs are being offset by pro-atherogenic drug effects. Potentially, relevant biomarkers are longitudinal measurement of circulating cardiotoxic CD4 + CD28 null T cells and atheroprotective Tregs which participate in plaque formation and destabilization and whose respectively increased and decreased concentration is associated with active inflammation in atherosclerosis. Also, the causal role of alloantibodies (including DSA), autoantibodies, and of genetic traits in donor and acceptor should be further explored. Possibly, integration of these and other markers can further contribute to the individualization of immunosuppression after transplantation in the era of personalized medicine.
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